Navigation Links
Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Date:2/15/2008

- Poster Presented at ASCO Genitourinary Cancers Satellite Symposium -

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it is presenting safety and efficacy data in prostate cancer patients from its Phase 1 study of picoplatin, the Company's lead product candidate, at the 2008 Genitourinary (GU) Cancers Symposium, a meeting of the American Society of Clinical Oncology (ASCO) that is being held in San Francisco.

The poster presentation includes safety and efficacy data from a dose-escalating Phase 1 study of picoplatin in combination with full-dose docetaxel (75 mg/m squared) with prednisone as a first-line treatment for metastatic hormone refractory prostate cancer (mHRPC). The Phase 1 study sought to establish the maximum tolerated dose of picoplatin and provide information on the safety and efficacy of picoplatin in combination with docetaxel and prednisone, the standard of care for the first-line treatment of mHRPC.

"The data we have generated with picoplatin in prostate cancer indicate a PSA (prostate specific antigen) response of 65 percent which suggests an improvement compared to docetaxel therapy alone," said Jerry McMahon, Ph.D., chairman and CEO of Poniard Pharmaceuticals. "In addition, the tolerability of picoplatin with full-dose docetaxel supports our ongoing Phase 2 study that we believe will confirm and extend these initial findings. The combination of platinums and taxanes, such as docetaxel, is used to treat many other solid tumors, such as non-small cell and ovarian cancers. We believe that our data support additional evaluation of picoplatin and docetaxel combinations in t
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between dropping ... health was forgotten. But Audicus , a next-generation ... better this new year. Hearing loss is ... aging population, though it is often unaddressed. Forty-eight million ... has a hearing aid, mainly due to price. Hearing ...
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... Jan. 6, 2011 /PRNewswire-Asia-FirstCall/ -- Nutrastar International Inc. (OTC ... "Company"), a leading producer and supplier of premium branded ... the Company will be participating in the upcoming Cowen ... the Westin New York at Times Square (270 West ...
... 2011 Viveve, Inc. , a development stage ... the European CE (Conformite Europeenne) mark for the use ... laxity of the vaginal introitus (opening), after childbirth, to ... ) "The CE mark is a key ...
Cached Medicine Technology:Nutrastar to Present at the Cowen and Company 9th Annual Consumer Conference in NYC 2Nutrastar to Present at the Cowen and Company 9th Annual Consumer Conference in NYC 3Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity 2
(Date:12/19/2014)... drug users who also use cocaine and amphetamines have ... users, a new study finds. "We know that ... attempt and completed suicide," Didier Jutras-Aswad, a psychiatry professor ... news release. "However, there are many different profiles of ... users were actually more likely to attempt suicide." ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- The cost of ... well-being, a new study finds. Researchers examined data ... been diagnosed with colorectal or lung cancer. Of those ... cancer-free, and more than 100 had advanced cancer. ... to pay their medical bills, which was linked with ...
(Date:12/19/2014)... NC (PRWEB) December 19, 2014 Surviving Mesothelioma ... and EPA information indicates that these pipes can leach asbestos ... go to the full story on the Surviving Mesothelioma ... the erosion of natural asbestos deposits, decaying water mains made ... drinking water. , To protect consumers from mesothelioma ...
(Date:12/19/2014)... Dennis Thompson HealthDay ... -- Ebola,s entrance into the United States -- along ... mumps outbreak -- have highlighted cracks in the nation,s ... new health policy report released Thursday. Half of ... respond to infectious disease outbreaks. That was the main ...
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... The top executive search firm in the healthcare industry, ... healthcare executives into organizations. , Johnson Memorial Hospital ... to the residents of Johnson County and the surrounding ...
Breaking Medicine News(10 mins):Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... benefits which could run parallel to that of penicillin ... of Medicine at Harvard Medical School. ,Professor ... levels in unrefined cocoa has the potential to combat ... world viz. stroke, heart ailments, cancer and diabetes. He ...
... German scientists have found that the scent of ... The scientists at the University of Lubeck, ... programmed bursts of rose odors, while they were memorizing cards ... sent off to sleep with electrodes connected to their heads. ...
... Hopkins emergency medicine specialists have developed a tool ... potential to overwhelm services//. ,The Electronic Mass ... calculates the impact of such crises as a ... accounting for such elements as numbers of victims, ...
... including those with a family history of the disease, should ... to prevent the disease. ,This is the first ... taking medicines to prevent colorectal cancer. After reviewing the latest ... potential harms of taking more than 300 mg per day ...
... who devote more time to physical activity have a ... next 15 years, according to new research// . ... physical activity is actually causally related to hypertension,” said ... an epidemiologist at the University of Minnesota in Minneapolis, ...
... conducted on mice shows that more copper in everyday ... was conducted by scientists at the University of Louisville ... ,Their studies show that giving copper supplements ... by preventing heart enlargement. The study will be published ...
Cached Medicine News:Health News:Scent of a Rose may Give More Than Pleasure 2Health News:Aspirin Or NSAIDs Will not Prevent Colorectal Cancer 2Health News:Physical Activity Reduces Hypertension Risk in Young Adults 2
Gentle-Flo® Vactrol® Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
... 8 Suction Catheters With Contro-Vac Valve and ... Low-Risk Respiratory Suctioning, ,Medline's 6 and ... DeLee Tips are the optimal tools for ... a forward placed suction valve to minimize ...
... available in two tip styles- ... with staggered eyes, and the ... of catheter valve options, SAFE-T-VAC ... control with virtually no residual ...
... Our Tri-Flo® suction catheter design ... to your patients while still providing ... pediatric catheters (5/6, 8 or 10 ... facilitate proper catheter placement. Our complete ...
Medicine Products: